HIV/AIDS not only represents the most severe epidemic in modern times, but also the
greatest public health challenge in history. The response of the scientific community has …

Introduction Antiretroviral therapy (ART) in resource-limited settings has expanded in the last
decade, reaching> 8 million individuals and reducing AIDS mortality and morbidity …

Background The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors
(NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line …

Lopinavir/ritonavir (Kaletra®) is an orally administered coformulated ritonavir-boosted
protease inhibitor (PI) comprising lopinavir and low-dose ritonavir. It is indicated, in …

Background Standard-of-care antiretroviral therapy (ART) uses a combination of drugs
deemed essential to minimise treatment failure and drug resistance. Protease inhibitors are …

The overall purpose of these guidelines is to provide guidance on best clinical practice in
the treatment and management of adults with HIV infection on antiretroviral therapy (ART) …

Background: In resource-limited settings, many patients, with no prior protease inhibitor (PI)
treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen …

Background The unparalleled success of combination antiretroviral therapy (cART) is based
on the combination of three drugs from two classes. There is insufficient evidence whether …

Objetivo Actualizar las recomendaciones sobre tratamiento antirretroviral (TAR) para
adultos con infección por el VIH-1. Métodos Este documento ha sido consensuado por un …

Since the advent of highly active antiretroviral therapy (HAART), the treatment of human
immunodeficiency virus (HIV) infection has become more potent and better tolerated. While …